Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary. | Mult Scler;28(5): 695-696, 2022 04. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary.

Gratch, Daniel; Zhovtis Ryerson, Lana.

Gratch D; NYU Langone Health, New York, NY, USA.
Zhovtis Ryerson L; NYU Langone Health, New York, NY, USA.

Mult Scler ; 28(5): 695-696, 2022 04.

Article in English | MEDLINE | ID: covidwho-1808138

Subject(s)

Multiple Sclerosis; Cell Count; Drug Administration Schedule; Humans; Multiple Sclerosis/drug therapy

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Multiple Sclerosis Limits: Humans Language: English Journal: Mult Scler Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: 13524585211067708

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Multiple Sclerosis Limits: Humans Language: English Journal: Mult Scler Journal subject: Neurology Year: 2022 Document Type: Article Affiliation country: 13524585211067708